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CASE REPORTSAvoidance of intubation during acute exacerbation of chronic
obstructive pulmonary disease for a lung transplant candidate using
extracorporeal carbon dioxide removal with the HemolungFrank Bonin, MD,a Urte Sommerwerck, MD,a Laura W. Lund, PhD,b and Helmut Teschler, MD, PhD,a
Essen, Germany, and Pittsburgh, PaFor patients with severe chronic obstructive pulmonary
disease (COPD) experiencing an acute exacerbation, the
necessity for invasive mechanical ventilation (IMV) not
only is associated with high mortality1,2 but also can be
particularly disadvantageous to a patient also awaiting
lung transplantation.3 In this case report, we describe our
use of a novel extracorporeal carbon dioxide removal (EC-
CO2R) device for partial respiratory support in such a patient
whowas failing support with noninvasive ventilation (NIV).
The Hemolung Respiratory Assist System (ALung Technol-
ogies, Pittsburgh, Pa) provided ECCO2R at a blood flow of
approximately 500 mL/min through a single 15.5F venove-
nous cannula inserted percutaneously through the left femo-
ral vein.4,5 This casewas conducted as part of the first human
clinical feasibility study of theHemolung device andwas the
first time the device was used at our facility.6
CLINICAL SUMMARY
A 50-year-old man was admitted for infection-induced
exacerbation of severe COPD. The patient had a history of
emphysema before and after bulla and right apex pulmonary
resection, pulmonary cachexia, past nicotine abuse, and a di-
agnosis of Global Initiative for Chronic Obstructive Lung
Disease grade IV COPD (forced expiratory volume in 1 sec-
ond of 14% predicted). He was receiving long-term oxygen
therapy with intermittent NIV. One month before hospital
admission, the patient was listed for bilateral lung transplant
with normal priority status because of increasing deteriora-
tion ofCOPD.After admission, the patient’s conditionwors-
ened, requiring antibiotic treatment and continuous NIV.
Three days after admission, the patient decompensated
and was transferred on an emergency basis to the intensive
care unit with an arterial carbon dioxide tension (PaCO2) ofFrom Ruhrlandklinik,a West German Lung Center at University Hospital of Essen
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The Journal of Thoracic and Ca90 mm Hg and pH of 7.23. A thoracic x-ray revealed a left
spontaneous pneumothorax. After immediate thoracic
drainage, the lung expanded and the pulmonary leakage
was eliminated. Overnight, despite continuous optimized
NIV, there was no improvement. The PaCO2 remained be-
tween 72 and 85 mm Hg, the respiratory rate was 30 to 40
breaths/min, and the pH was less than 7.3. The patient was
exhausted, and intubation seemed imminent but was contra-
indicated because of the pneumothorax.
The patient was informed about alternative methods of
extracorporeal carbon dioxide elimination that our hospital
could provide, including the Hemolung, which had been ap-
proved for an investigational feasibility study by our local
and national ethics committees. Detailed information was
provided regarding the benefits and risks of ECCO2R ther-
apy with the Hemolung. The patient opted for and gave his
consent to be treated with this device.
A 15.5F dual-lumen catheter was inserted percutaneously
without complication via the left femoral vein, and heparin
was administered in accordance with study protocol guide-
lines for anticoagulation (initial bolus of 80 U/kg, followed
by continuous systemic infusion at 18U/kg/h,with a target ac-
tivated partial thromboplastin time of 1.5-2.3 times baseline).
Immediately after initiation of ECCO2R therapy with the He-
molung, the patient’s respiratory rate decreased, at times to
less than 10 breaths/min. The patient became increasingly ac-
tive and intolerant of the NIVminimum set breathing rate and
was found to becomfortable and stablewithout aminimumset
rate. TheHemolung circuit bloodflow ranged from422 to 520
mL/min. The rate of carbon dioxide removal measured by the
Hemolung controller averaged 89  8.7 mL/min. Arterial
PaCO2 decreased from75 to 60mmHgafter commencing ther-
apy, but remained within a range of 60 to 55 mm Hg for the
durationof therapy, as shown inTable1.The clinical status im-
proved steadily and continuously during 6 days of treatment.
At the beginning of Hemolung therapy, discontinuing
NIV was not possible. By day 3, the patient was off NIV
5 to 6 times for 15 minutes at a time. Drinking and recovery
from pressure sores were possible. By day 5, the patient was
able to breathe for 16 hours. On day 6, the patient had com-
pensated to such a degree to wean from Hemolung support.
The catheter was removed with normal coagulation values
and no additional bleeding. The patient was then supported
intermittently with NIV.
The primary complication was bleeding due to higher
than targeted activated partial thromboplastin time values.rdiovascular Surgery c Volume 145, Number 5 e43
TABLE 1. Summary of arterial blood gases and noninvasive ventilatory parameters before and during extracorporeal support with the Hemolung
(ALung Technologies, Pittsburgh, Pa)
On admission to ICU
During Hemolung therapy
Hour 2 Hour 24 Hour 48 Hour 132 (weaning)
pH 7.23 7.34 7.40 7.40 7.38
PaCO2 (torr) 90 67.4 61.7 55.9 56.2
Peak inspiratory pressure (mm Hg) — 20 20 20 20
Peek expiratory pressure (mm Hg) — 6 5 5 5
FIO2 — — 26% 32% 28%
Respiratory rate 30-40 18 16 13 14
Minute ventilation — 8.0 6.4 4.8 8.7
ICU, Intensive care unit; PaCO2, arterial carbon dioxide tension; FIO2, inspired oxygen fraction. Data from Burki and colleagues.
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Case ReportsAfter titrating the heparin dosage, the bleeding ceased
within 2 hours and did not reappear; no transfusion was nec-
essary. There were no other complications during or after
extracorporeal support. Plasma-free hemoglobin levels
remained below the baseline measurement of 6.5 mg/dL.
Platelet counts decreased over the course of extracorporeal
therapy as expected without serious effects.
During treatment with the Hemolung, the patient was
given a high-urgent status for the transplant waiting list.
The patient successfully received a bilateral lung transplant
31 days after Hemolung support and was discharged 63
days post-transplant.
CONCLUSIONS
The risk of bleeding is present with any form of extracorpo-
real support, including hemodialysis. The alternative to EC-
CO2R therapy would have been IMV, which is associated
with different but more serious risks, as well as significantly
greater patient discomfort and quality of life. Compared with
ECMO systems used for full respiratory or cardiopulmonary
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Chest. 2013;143:678-86.Swyer–James–MacLeod syndrome with renal ectopy misdiagnosed
as pneumothorax and chest tube drained: Case study
Bayram Metin, MD,a Emre €Ozkan, MD,b Murat Saric¸am, MD,c and Olgun Kadir Ariba, MD,d Yozgat,
Amasya, Agrı, and Ankara, TurkeySwyer–James–MacLeod syndrome is characterized by
hyperlucency caused by an increase in aeration and
a decrease in vascularity in a lung lobe. The syndrome usu-
ally develops as a result of recurrent pulmonary infections
in childhood and should be discriminated from pneumotho-
rax and other diseases causing unilateral hyperlucency on
chest radiography. We present a patient with a diagnosis
of Swyer–James–MacLeod syndrome with a renal anomaly
who received a mistaken diagnosis of pneumothorax and
had a chest tube inserted.ery c May 2013
